| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -4,273 | -21,695 |
| Net decrease in cash and cash equivalents | -4,273 | -21,695 |
| Cash and cash equivalents at beginning of period | 52,889 | - |
| Cash and cash equivalents at end of period | 48,616 | - |
Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. (SPRO)